Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Boosted by abrdn plc

abrdn plc lifted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 442.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,230 shares of the specialty pharmaceutical company’s stock after purchasing an additional 45,860 shares during the period. abrdn plc owned about 0.09% of Jazz Pharmaceuticals worth $6,916,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Los Angeles Capital Management LLC raised its position in shares of Jazz Pharmaceuticals by 558.6% during the third quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock worth $41,780,000 after purchasing an additional 273,764 shares during the period. Pacer Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 28.1% during the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after buying an additional 224,865 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Jazz Pharmaceuticals by 242.8% in the third quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock worth $35,023,000 after buying an additional 191,648 shares during the period. Aristotle Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the third quarter worth approximately $22,748,000. Finally, Federated Hermes Inc. raised its holdings in shares of Jazz Pharmaceuticals by 1,105.6% during the third quarter. Federated Hermes Inc. now owns 123,635 shares of the specialty pharmaceutical company’s stock valued at $16,003,000 after acquiring an additional 113,380 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Up 1.9 %

JAZZ stock opened at $109.46 on Friday. The business has a fifty day moving average of $118.25 and a 200-day moving average of $121.81. The company has a market cap of $6.90 billion, a P/E ratio of 17.89, a PEG ratio of 1.50 and a beta of 0.59. Jazz Pharmaceuticals plc has a twelve month low of $106.61 and a twelve month high of $146.70. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. As a group, equities research analysts expect that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $195.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Stifel Nicolaus increased their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. UBS Group lowered their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research note on Friday, March 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $195.08.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were bought at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Philip L. Johnson acquired 12,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.